Susvimo® (Ranibizumab Injection) – Commercial Medical Benefit Drug Policy
Defines medical necessity criteria, continuation criteria, and applicable procedure/diagnosis codes for Susvimo (ranibizumab intravitreal implant J2779) under the commercial medical benefit.
Revised list of applicable diagnoses for which Susvimo is proven and medically necessary; added diabetic retinopathy (DR).
Updated Clinical Evidence, FDA, and References sections to reflect the most current information.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.